Skip to content
  • Saturday, 12 September 2026
  • 6:25 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 18, 2026 0

Eli Lilly and Company has announced groundbreaking Phase 3 results for its investigational triple agonist, retatrutide, demonstrating significant efficacy in…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 11, 2026 0

Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jul 1, 2026 0

Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…

Read More
Laboratory Automation & Robotics

Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo

Lana Keisha Jun 22, 2026 0

The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…

Read More
Laboratory Automation & Robotics

Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo

Lana Keisha Jun 15, 2026 0

Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…

Read More
Pharmaceutical R&D

Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership

Teuku Ryan May 21, 2026 0

Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…

Read More
Molecular & Cell Biology

Naked Mole Rat Gene Transfer to Mice Offers Glimpse into Extending Mammalian Healthspan

Angie Faith May 10, 2026 0

In a groundbreaking development that blurs the lines between species and aging research, scientists have successfully transferred a key longevity-associated…

Read More
Environmental & Analytical Chemistry

A Blood Filter Shows Promise in Extending Pregnancies Affected by Preeclampsia

Abdurrohim Arsyad May 5, 2026 0

A groundbreaking, albeit small-scale, clinical trial has offered a glimmer of hope for pregnant individuals battling preeclampsia, a serious and…

Read More
Biotech & Genetic Research

The biotech bi-weekly: genome editing, life-extending therapeutics, an early-stage biotech hub and more

Jia Lissa Mar 18, 2026 0

The biopharmaceutical and biotechnology sectors have recently experienced an extraordinary period of accelerated activity, marked by a rapid succession of…

Read More
Unraveling the Mysteries of the Bundibugyo Virus: A Race Against a Rare and Deadly Outbreak in the Democratic Republic of CongoProfessor Albert Heck Honored with John B. Fenn Award for Transformative Contributions to Biomolecular Mass SpectrometryPharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.AI Lab Result Interpretation Gains Traction with Patients, but Raises Accuracy and Validation Concerns for Clinical Laboratories
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy PorustobartScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ